Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 7/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29570584 | 1.00 | KCNN4 (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29570767 | 1.00 | KCNN4 (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24370406 | 1.00 | KCNN4 (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27211967 | 1.00 | KCNN4 (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27230743 | 1.00 | KCNN4 (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24370405 | 1.00 | KCNN4 (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29570865 | 0.81 | KCNN4 (0.47) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29570545 | 0.81 | KCNN4 (0.47) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29570725 | 0.81 | KCNN4 (0.47) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29571174 | 0.79 | CYP26A1 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116802181-A | Triazolopyridine compounds as kinase inhibitors | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4229056-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022086828-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086828-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | KCNN4 3343/4885HDAC3 956/4885HDAC4 1667/4885 |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | KCNN4 3343/4885HDAC3 956/4885HDAC4 1667/4885 |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | KCNN4 3343/4885HDAC3 956/4885HDAC4 1667/4885 |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | KCNN4 3343/4885HDAC3 956/4885HDAC4 1667/4885 |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | KCNN4 3343/4885HDAC3 956/4885HDAC4 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.